The Asia-Pacific region (excluding Korea, China, Japan, India) has emerging biotechnology companies focused on developing treatments for neurodegenerative diseases. Singapore has positioned itself as a regional hub for biotech research, while Australia and New Zealand have active neuroscience research communities.
ES Revive is a Singapore-based biotechnology company focused on developing treatments for age-related diseases, including neurodegenerative conditions.
- Headquarters: Singapore
- Focus: Alzheimer's disease, aging-related disorders
- Approach: Novel therapeutic modalities
- Status: Research and development
Virometix is a Singapore biotech focused on viral vector technologies for gene therapy.
- Headquarters: Singapore
- Focus: Gene therapy for neurological disorders
- Approach: Novel viral vectors
- Status: Preclinical
Mirxes is a Singapore company focused on microRNA diagnostics and therapeutics.
- Headquarters: Singapore
- Focus: Alzheimer's disease diagnostics
- Approach: Biomarker development
- Status: Diagnostics development
Craytor Therapeutics is a biotech company developing treatments for neurodegenerative diseases.
- Headquarters: Singapore
- Focus: Alzheimer's disease, Parkinson's disease
- Approach: Small molecule therapeutics
- Status: Research
Activ8 Neuro is an Australian biotech focused on neurological disorders.
- Headquarters: Melbourne, Victoria
- Focus: Alzheimer's disease, Parkinson's disease
- Approach: Novel drug delivery
- Status: Preclinical
Neurizon is an Australian company focused on neurodegenerative disease therapeutics.
- Headquarters: Sydney, New South Wales
- Focus: ALS, Alzheimer's disease
- Approach: Neuroprotective compounds
- Status: Research
Alterity Therapeutics is an Australian biotech company developing treatments for neurodegenerative diseases.
- Headquarters: Melbourne, Victoria
- Focus: Parkinson's disease, Huntington's disease
- Key programs:
- PBT434 - Novel small molecule
- Status: Clinical trials
Actinogen Medical is an Australian biotech focused on neurological disorders, developing treatments for Alzheimer's disease and major depressive disorder.
- Headquarters: Sydney, New South Wales
- Focus: Alzheimer's disease, cognitive impairment
- Key programs:
- Xanamem® (emestedastat) - 11β-HSD1 inhibitor targeting brain cortisol
- Status: Phase 2b/3 clinical trials (XanaMIA trial)
- Trial: XanaMIA Phase 2b/3 Alzheimer's disease trial enrollment closed; topline results expected November 2026
- Recent Updates (2025-2026): An independent Data Monitoring Committee conducted a positive interim analysis and recommended the trial continue without amendment, citing unblinded safety and efficacy data supporting completion. The company secured funding beyond the trial results following a $16.8 million placement and share purchase plan, plus $7.4 million in FY2025 R&D tax incentives from the Australian Tax Office. Additional programs target cognitive impairment in major depressive disorder and behavioral symptoms in Fragile X Syndrome.
Neurotech is an Australian company developing neurotechnology devices.
- Headquarters: Brisbane, Queensland
- Focus: Parkinson's disease, movement disorders
- Approach: Deep brain stimulation technology
- Status: Medical devices
SYNthesis is an Australian contract research organization with neuroscience expertise.
- Headquarters: Melbourne, Victoria
- Focus: CNS drug development
- Approach: Preclinical research services
- Status: Research services
TaiRx is a Taiwanese biotech developing anti-aging and neuroprotective therapeutics.
- Headquarters: Taipei, Taiwan
- Focus: Alzheimer's disease, aging
- Approach: Novel small molecules
- Status: Research
Scinexxic is a Taiwanese company focused on neurological disease therapeutics.
- Headquarters: Taipei, Taiwan
- Focus: Alzheimer's disease, Parkinson's disease
- Approach: Protein aggregation inhibitors
- Status: Preclinical
¶ New Zealand Companies
NZ Neuro Research is a New Zealand company focused on neurological disease research.
- Headquarters: Auckland
- Focus: Neurodegeneration research
- Approach: Academic partnerships
- Status: Research
Cognitive Health Research is focused on Alzheimer's disease research in New Zealand.
- Headquarters: Wellington
- Focus: Alzheimer's disease
- Approach: Prevention strategies
- Status: Research
¶ Academic and Research Institutions
- Agency for Science, Technology and Research (A*STAR): Neuroscience research
- National Neuroscience Institute (NNI): Clinical research
- Duke-NUS Medical School: Neurodegeneration research
- Florey Institute of Neuroscience and Mental Health: Alzheimer's research
- Brain Institute (University of Queensland): Neurodegeneration
- Monash University: CNS research
- University of Sydney: Neuroscience research
- Academia Sinica: Neuroscience research
- National Taiwan University: Neurobiology research
- National Research Foundation: Biotech funding
- EDB (Economic Development Board): Biotech incentives
- National Health and Medical Research Council (NHMRC): Research funding
- Medical Research Future Fund: Biomedical research
Major pharmaceutical companies conduct clinical trials for neurodegenerative diseases at sites in:
- Singapore (National Neuroscience Institute)
- Australia (multiple sites)
- Taiwan (major medical centers)